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Development  of  hepatocellular  carcinoma,  in  common 
with other types of tumor, is considered to be a multistep 
process. Genetic and epigenetic alterations accumulate in 
regulatory genes, leading to activation of oncogenes and 
inactivation or loss of tumor suppressor genes [1]. The 
concept  that  hepatocellular  carcinoma  is  a  disease  of 
epigenetic as well as genetic alterations has been valid­
ated in the past two decades. The epigenetic pathway is, 
in contrast to the genetic events, a reversible alteration 
that is not caused by primary DNA sequence changes.
There are three main epigenetic mechanisms: (i) hyper­
methylation of CpG islands in promoter sequences lead  ing 
to silencing of tumor suppressor genes; (ii) DNA hypo­
methylation, which causes genomic instability or induc­
tion of genes involved, for example, in cell growth and 
invasion [2]; and (iii) histone modification, which affects 
chromatin conformation. Because epigenetic mecha  nisms 
may  function  as  an  interface  between  environmental 
factors  and  the  genome  [3],  deregulation  of  the  epi­
genome by environmental stressors (for example, hepatitis 
B  and  hepatitis  C  viruses,  chronic  alcohol  intake,  and 
afla  toxins) is believed to disrupt cellular processes and 
contribute to the risk of hepatocellular carcinoma. The 
early  appearance  of  epigenetic  changes  makes  them 
attractive  targets  for  biomarker  discovery.  Moreover, 
drugs to reverse the epigenetic abnormalities are under 
development  and  some  have  already  been  approved. 
Cancer epigenetics is continuously translating into clinical 
practice and will help to optimize cancer diagnostics and 
treatment. The recent observation by Schaeffeler et al. in 
Genome Medicine that uptake transporters for anticancer 
drugs  are  epigenetically  regulated  in  hepatocellular 
carcinoma adds an important piece of information to the 
growing body of research on cancer epigenetics [4]. The 
potential  implications  of  these  findings  for  biomarker 
development  and  pharmacotherapy  of  hepatocellular 
carcinoma will be discussed.
Epigenetics of organic cation transporter genes in 
cancer
Whereas previous work has focused mainly on the role of 
CpG hypermethylation for regulating oncogenes, tumor 
suppressor genes or DNA repair genes in hepatocellular 
carcinoma, Schaeffeler et al. [4] investigated the role of 
DNA methylation in the expression of specific members 
of the solute carrier (SLC) gene superfamily, namely the 
organic cation transporter genes SLC22A1 to SLC22A3 
(encoding  proteins  OCT1,  OCT2  and  OCT3,  respect­
ively).  In  normal  hepatocytes,  SLC22A1  (solute  carrier 
family  22  member  1),  which  encodes  OCT1  (organic 
cation transporter 1), is highly expressed and is respon­
sible for the uptake of nutrients, metabolites and xeno­
biotics. The transporter is also crucial for the uptake of 
some drugs [5]. Whereas lipophilic antineoplastic agents 
can  enter  cells  by  passive  diffusion,  uptake  of  charged 
hydrophilic  agents,  such  as  the  anticancer  compounds 
imatinib, cisplatin, oxaliplatin, picoplatin, irinotecan and 
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© 2012 BioMed Central Ltdpaclitaxel,  requires  active  transport.  Indeed,  OCT1 
transports these six drugs and thereby contributes to the 
susceptibility  of  cancer  cells  to  these  antineoplastic 
drugs.
cDNA microarray studies have demonstrated decreased 
expression of SLC22A1 in hepatocellular carcinoma com­
pared with normal liver tissue. However, the mechanisms 
of downregulation have remained unclear. Based on their 
findings, Scheffeler et al. [4] suggest SLC22A1 promoter 
hypermethylation as an important mechanism. Epigenetic 
silencing  of  OCT1  in  hepatocellular  carcinoma,  as 
demonstrated by Schaeffeler et al. [4], most likely impairs 
uptake  of  some  anticancer  drugs  into  hepatocellular 
cancer cells and thus is likely to impair their efficacy. This 
might,  in  part,  explain  the  low  response  rates  and 
uncertain survival benefit of, for example, cisplatin­based 
chemotherapy for hepatocellular carcinoma. In contrast, 
the tyrosine kinase inhibitor sorafenib, which does not 
appear to require active transport to enter cells [6], induces 
better disease control, significantly extends survival, and 
has  become  a  standard  first­line  option  for  systemic 
treatment of advanced hepatocellular carcinoma.
Biomarkers to guide individualization of 
chemotherapy
Given the important role of OCT1 in cancer cell uptake 
and thus treatment efficacy of several anticancer drugs, 
methylation of SLC22A1 might be used as a marker for 
predicting therapeutic response. The work by Schaeffeler 
et  al.  [4]  has  demonstrated  substantial  interindividual 
variability  in  the  degree  of  SLC22A1  methylation  and 
SLC22A1  production,  as  revealed  by  histochemical 
analysis. It is tempting to speculate that patients with a 
high  SLC22A1  methylation  phenotype  and  silenced 
transporter  expression  may  exhibit  chemoresistance, 
whereas patients with a low methylation phenotype and 
enhanced transporter expression may respond to chemo­
therapy.  Most  recently,  Ma  et  al.  [7]  provided  another 
example of the involvement of epigenetic mechanisms in 
determining  chemoresistance  and  chemosensitivity  in 
hepatocellular  carcinoma.  MIR193A  promoter  hypo­
methy  la  tion is associated with transcriptional induction 
of  the  microRNA  193a­3p,  which  targets  the  serine/
arginine­rich splicing factor 2 (SRSF2). SRSF2 sensitizes 
hepatocellular cancer cells to the chemotherapeutic drug 
5­fluorouracil  via  upregulation  of  the  proapoptotic 
splicing form of caspase 2. Accordingly, its repression by 
microRNA 193a­3p reduces sensitivity of hepatocellular 
cancer  cells  to  5­fluorouracil  [7].  This  experimental 
obser  vation suggests that the DNA methylation state of 
MIR193A  could  function  as  a  marker  to  predict  the 
therapeutic response to 5­fluorouracil.
Biomarker for cancer screening
As  well  as  using  DNA  methylation  as  a  biomarker  for 
personalizing chemotherapy, evidence has emerged that 
detection  of  abnormal  promoter  CpG  island  hyper­
methylation  is  also  a  potential  biomarker  for  risk  of 
developing cancer. DNA methylation in adjacent histo­
logically normal liver tissue of hepatocellular carcinoma 
has  been  reported  from  several  groups  and  is  now 
accepted  as  an  early  event  in  cancer  development  [8]. 
Thus,  aberrant  DNA  methylation  might  be  useful  for 
early  cancer  detection  and  for  predicting  prognosis. 
Comparisons of CpG island methylation in hepatocellular 
carcinoma  with  that  in  adjacent  tumor­free  tissue  or 
normal  control  livers  have  produced  a  continuously 
expand  ing  list  of  potential  marker  genes.  Interestingly, 
Schaeffeler et al. [4] demonstrated that SLC22A1 belongs 
to a group of genes with progressively increasing CpG 
methylation, from normal liver to hepatocellular carci­
noma,  with  intermediate  methylation  in  precancerous 
tissues  (that  is,  in  adjacent  tumor­free  tissue).  Similar 
methylation changes related to the progression of malig­
nant transformation have been observed previously for 
other  genes,  including  RASSF1A,  PRDM14  and  TBX4, 
which encode Ras association domain family member 1, 
PR domain containing 14 and T­box 4, respectively. [8]. 
Therefore,  the  CpG  methylation  phenotype  of  these 
genes may serve as a marker for early cancer detection or 
assessing cancer risk.
As biomarker strategies move towards actual clinical 
practice,  these  proof­of­principle  findings  should  be 
validated in larger patient cohorts. For detection of other 
tumors, such as colorectal and lung cancers, assays that 
test methylation patterns of marker genes in DNA from 
the  stool,  blood  or  bronchoalveolar  lavage  are  already 
commercially offered to clinicians [9].
Epigenetic therapy for cancer
The results reported by Shaeffeler et al. [4] also highlight 
the  clinical  implications  of  epigenetic  modulation  of 
trans  porter  expression.  DNA  methyltransferase  inhibi­
tors, such as decitabine, have already been approved for 
treatment  of  lymphomas  and  are  being  tested  as  a 
therapeutic option against various solid tumors. If these 
agents  are  concomitantly  administered  with  classical 
anticancer drugs, the resulting induction of transporter 
expression  may  influence  the  disposition  and  effect  of 
these anticancer drugs. Specifically, repression of OCT1 
might be reversed by treatment with the DNA methyl­
transferase  inhibitor  decitabine,  enhancing  uptake  of 
cisplatin  into  hepatocellular  tumor  cells.  However,  the 
fascinating  possibility  of  overcoming  the  problem  of 
chemoresistance with an epigenetic therapy awaits proof 
of concept.
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